BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
Top Page
BridgeBio Pharma
(NASDAQ:BBIO)
Select Model
Select Model
Rating:52Neutral
Price Target:
$70.00
▼(-2.68% Downside)
Action:ReiteratedDate:03/31/26
The score is held back primarily by weak current financials (large losses, heavy cash burn, and negative equity). Offsetting this, the latest earnings update and pipeline/commercial progress point to improving fundamentals over time, while technicals are neutral and valuation remains challenging due to ongoing losses and no dividend.
Positive Factors
Revenue acceleration & high gross margins
Rapid revenue growth paired with exceptionally high gross margins indicates the company’s commercial product (Atruby) scales profitably at the unit level. This durable mix supports operating leverage as launches expand, improving long-term cash conversion once fixed commercial costs stabilize.
Negative Factors
Persistent heavy cash burn
Sustained large negative operating and free cash flows reflect high R&D and SG&A spend during commercialization scale-up. Continued cash consumption makes the company reliant on external financing until multiple programs reach commercial scale and can stress flexibility if launch timing slips.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue acceleration & high gross margins
Rapid revenue growth paired with exceptionally high gross margins indicates the company’s commercial product (Atruby) scales profitably at the unit level. This durable mix supports operating leverage as launches expand, improving long-term cash conversion once fixed commercial costs stabilize.
Read all positive factors
BridgeBio Pharma (BBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.94B
Dividend YieldN/A
Average Volume (3M)2.37M
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue Growth62.46%
EPS Growth-73.59%
CountryUS
Employees725
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.00
Shares Outstanding193,862,870
10 Day Avg. Volume1,721,591
30 Day Avg. Volume2,371,146
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)-7.27
Price to Sales (P/S)30.05
P/FCF Ratio-33.75
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue32.93
Enterprise Value/Gross Profit34.89
Enterprise Value/Ebitda-26.56
Forecast
1Y Price Target
$101.63Price Target Upside41.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-1.96
Revenue Forecast (FY)$919.87M
BridgeBio Pharma Business Overview & Revenue Model
Company Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage ...
How the Company Makes Money
BridgeBio makes money primarily through (1) product revenue from commercialized therapies and (2) collaboration, licensing, and related payments tied to its pipeline.
1) Product revenue: When BridgeBio has an approved product on the market, it ge...
BridgeBio Pharma Key Performance Indicators (KPIs)
Any
Revenue by Segment
Highlights how much revenue each business segment generates, providing insight into which areas are driving growth and which may need strategic adjustments.
Highlights how much revenue each business segment generates, providing insight into which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyBridgeBio Pharma Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call conveyed a largely positive outlook driven by robust commercial momentum for Atruby, multiple positive Phase 3 readouts (notably infigratinib in achondroplasia), improving cash runway via convertible notes, and a clear path to becoming cash-generative by 2028. These progress points materially de-risk the pipeline and support substantial future value creation. Near-term headwinds include a sizable SG&A and operating expense ramp as the company builds commercial infrastructure, continued net cash consumption during the scale-up phase, concentrated current revenue in one product, and external IP/legal uncertainty around tafamidis that has contributed to share-price volatility. Overall, the positives (strong revenue growth, multiple successful late-stage readouts, solid balance sheet actions, and clear launch plans) outweigh the lowlights, though execution and legal risks remain.Positive Updates
Strong Atruby commercial performance
Atruby net product revenue of $146,000,000 in Q4 2025 and $362,400,000 for full year 2025; total company revenue of $154,200,000 in Q4 and $502,100,000 for FY2025 (FY2025 revenue up ~$280.2M, ~126% year-over-year). Company reported 35% quarter-over-quarter growth in net product revenue (Q4) and >25% NBRx share as of 12/31/2025. As of Feb 20, 2026, Atruby had 7,804 unique patient prescriptions written by 1,856 unique prescribers, demonstrating accelerating new patient growth and prescriber depth.
Negative Updates
Large operating expense increase and continued net cash consumption
Total operating costs and expenses were $293,700,000 in Q4 2025 (up $61,800,000 vs prior-year quarter, ~+26.6%) and $1,000,000,000 for FY2025 (up $210,600,000 vs FY2024, ~+25.8%). The increases were primarily driven by SG&A (Q4 SG&A up $63,300,000; FY2025 SG&A up $242,300,000) as the company scales commercial operations. Company used $446,000,000 of cash for the year net of revenue in the prior year, underscoring continued net cash consumption while commercialization ramps.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Atruby commercial performance
Atruby net product revenue of $146,000,000 in Q4 2025 and $362,400,000 for full year 2025; total company revenue of $154,200,000 in Q4 and $502,100,000 for FY2025 (FY2025 revenue up ~$280.2M, ~126% year-over-year). Company reported 35% quarter-over-quarter growth in net product revenue (Q4) and >25% NBRx share as of 12/31/2025. As of Feb 20, 2026, Atruby had 7,804 unique patient prescriptions written by 1,856 unique prescribers, demonstrating accelerating new patient growth and prescriber depth.
Read all positive updates
Company Guidance
Management guided that cash burn (which was $446 million net of revenue in 2025) should roughly hold steady through 2026 and begin declining by late 2027 as Atruby revenues ramp, with the pipeline expected to start generating cash in late 2027 and become a cash‑generation engine by 2028 (management projects >$600 million in profit in 2028). They reiterated near‑term launch timing (Encalarec and BBP‑418 expected late 2026/early 2027), cited FY2025 total revenue of $502.1M (Q4 $154.2M), Atruby net product revenue of $362.4M for the year (Q4 $146.0M; Q4 net product revenue +35% QoQ; >25% NBRx share as of 12/31/2025), and 7,804 unique patient prescriptions written by 1,856 prescribers (7,804 new patient starts reported). They ended the year with $587.5M in cash, cash equivalents and marketable securities, completed $632.5M aggregate principal of 2033 convertible notes in Jan‑2026, noted FY2025 operating expenses of $1.0B (Q4 operating expenses $293.7M) driven by higher SG&A, reported Encalarec patient‑finding >1,700, and expect three programs to be PRV‑eligible (LGMD2I, infigratinib, Canavan) with PRVs currently valued at roughly $200–$300M.BridgeBio Pharma Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
22
Negative
Cash Flow
25
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 502.08M | 221.90M | 9.30M | 77.65M | 69.72M |
| Gross Profit | 473.81M | 218.02M | 6.86M | 74.21M | 66.60M |
| EBITDA | -672.88M | -436.83M | -565.47M | -397.44M | -533.83M |
| Net Income | -729.31M | -535.76M | -643.20M | -481.18M | -562.54M |
Balance Sheet | |||||
| Total Assets | 936.02M | 919.34M | 546.38M | 623.04M | 1.01B |
| Cash, Cash Equivalents and Short-Term Investments | 587.48M | 681.10M | 434.88M | 471.92M | 836.66M |
| Total Debt | 2.73B | 1.73B | 1.74B | 1.72B | 1.73B |
| Total Liabilities | 3.01B | 2.38B | 1.89B | 1.87B | 1.88B |
| Stockholders Equity | -2.08B | -1.47B | -1.35B | -1.25B | -870.41M |
Cash Flow | |||||
| Free Cash Flow | -447.01M | -521.66M | -529.03M | -425.81M | -546.18M |
| Operating Cash Flow | -445.91M | -520.73M | -527.72M | -419.49M | -497.93M |
| Investing Cash Flow | -24.49M | 60.78M | 54.03M | 453.15M | -200.83M |
| Financing Cash Flow | 359.29M | 748.46M | 451.54M | -13.13M | 736.45M |
BridgeBio Pharma Technical Analysis
Positive
71.93
Price Trends
71.26
Positive
72.35
Negative
61.71
Positive
Market Momentum
0.65
Negative
52.28
Neutral
57.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBIO, the sentiment is Positive. The current price of 71.93 is above the 20-day moving average (MA) of 71.06, above the 50-day MA of 71.26, and above the 200-day MA of 61.71, indicating a bullish trend. The MACD of 0.65 indicates Negative momentum. The RSI at 52.28 is Neutral, neither overbought nor oversold. The STOCH value of 57.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBIO.
BridgeBio Pharma Risk Analysis
BridgeBio Pharma disclosed 101 risk factors in its most recent earnings report. BridgeBio Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BridgeBio Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $11.42B | 15.12 | 36.88% | ― | 9.93% | 54.33% | |
68 Neutral | $10.81B | 32.67 | 5.82% | ― | 12.31% | 60.21% | |
58 Neutral | $19.79B | -4.07 | -30.15% | ― | -56.00% | -38.95% | |
55 Neutral | $11.74B | -45.32 | -43.76% | ― | 864.21% | 48.12% | |
52 Neutral | $13.94B | -20.69 | 39.18% | ― | 62.46% | -73.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $12.21B | ― | -68.82% | ― | 20.39% | 34.00% |
* Healthcare Sector Average
BBIO
BridgeBio Pharma
71.93
39.05
118.77%
BMRN
BioMarin Pharmaceutical
56.22
-3.21
-5.40%
EXEL
Exelixis
43.99
8.65
24.48%
IONS
Ionis Pharmaceuticals
73.89
46.12
166.08%
MDGL
Madrigal Pharmaceuticals
511.89
197.94
63.05%
MRNA
Moderna
50.11
23.44
87.89%
BridgeBio Pharma Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
BridgeBio Files NDA for LGMD2I/R9 Oral Therapy
Positive
Mar 30, 2026
On March 30, 2026, BridgeBio Pharma announced that it had submitted a New Drug Application to the FDA for its oral therapy BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9, a severe, progressive neuromuscular disease caused by FKRP gene ...
Business Operations and StrategyProduct-Related Announcements
BridgeBio Announces Positive Phase 3 Achondroplasia Trial Results
Positive
Feb 12, 2026
On February 12, 2026, BridgeBio reported positive topline results from its global Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia, showing a highly significant improvement in annualized height velocity over placebo at W...
Business Operations and StrategyStock BuybackPrivate Placements and Financing
BridgeBio Pharma Issues New Convertible Notes and Repurchases Stock
Positive
Jan 21, 2026
On January 21, 2026, BridgeBio Pharma, Inc. issued $632.5 million of 0.75% Convertible Senior Notes due 2033 in a Rule 144A private placement to qualified institutional buyers, including $82.5 million issued pursuant to the initial purchasers̵...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
BridgeBio Showcases Attruby Growth and Pipeline Progress
Positive
Jan 12, 2026
On January 12, 2026, BridgeBio Pharma used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to highlight strong early commercial traction for Attruby, its ATTR-CM therapy, reporting preliminary unaudited 2025 net product reven...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.